– Auragens Patient Education –

Creating the Evidence and Opening Doors

June 04, 2024    auragens.com
🔗 Share this newsletter on social media.

Mesenchymal Stem Cell treatments have made news for years. Whether it is Kobe Bryant utilizing them to heal an Achilles issue, Chris Hemsworth for his anti-aging protocol, or Jeremy Shockey using to maximize his wellness in his post-football career, traveling abroad for Stem Cell Treatments continues to make the news.

It is these celebrities and pro-athletes that have helped foster awareness as they travel oversees for treatment and make headlines. But the potential benefits of Stem Cell Treatments are not limited to those with celebrity. A part of Auragens’ mission is to create a regulatory atmosphere that allows these treatments to be available to all. And we do that by taking the notoriety that some of our patients have and then backing up with results with the science leading up to their treatments, and their benefits and therapeutic gains, as our evidence. And sharing as much as we can to bring transparency to this important work, with the full oversight and approval of the Government of Panama, and their Health Ministry.

POTENTIAL AND HURDLES

The Promise and Challenges of Human Umbilical Cord Mesenchymal Stem Cells in Treating Chronic Conditions

There are millions of patients that suffer from chronic conditions and degenerative diseases for which there are limited or no effective treatments. Conditions like osteoarthritis, spinal cord injuries, and certain autoimmune disorders that could potentially benefit significantly from hu-MSC treatments. And this is not even widely disputed:

“MSCs have been evidenced to modulate excess inflammatory responses in autoimmune- and inflammation-related diseases, such as graft-versus-host disease, inflammatory bowel disease, multiple sclerosis, sepsis, collagen-induced arthritis, and type 1 diabetes. In addition, several studies have shown that MSCs can improve allergic conditions, such as asthma, rhinitis, and dermatitis. However, owing to the limited proliferative capacity during ex vivo expansion, alternative sources are needed for clinical applications.” As the scientific journal, Nature (https://www.nature.com/articles/s41598-023-50258-2) recently recapped.

In layman’s terms, the scientific and medical community know that human umbilical cord Mesenchymal Stem Cells work, but as expansion of these cells is illegal in the United States, they are unable to source the biologics needed to create the evidence. (If one is ever told otherwise, as there are purported “Stem Cell Clinics” in the U.S., these are not the same and an individual should exercise serious caution prior to taking their claims at face value. But we will delve further into this in future newsletters.)

LEADING THE WAY

Pioneering Regenerative Medicine and Human Umbilical Cord Mesenchymal Stem Cell Treatments

Auragens, meanwhile, continues to help further the field of Regenerative Medicine and hu-MSC treatments by creating the much needed evidence time and time again. We are equipped internally to perform the research, development, and treatments that, in collaboration with our US partners, will allow the process to eventually be available to a much larger population.

And we directly address the concerns or objections that are frequently raised to ensure we are positioned to usher this standard of care into new markets.

From a cell creation and scientific standpoint this includes our ISO accredited laboratory and our use of continuing Good Manufacturing Practices (cGMP); Our monthly environmental testing and third party review of every cell lines to ensure efficacy and viability; Our donation program for umbilical cords for healthily born children as we start to screen mothers as they enter their second trimester of pregnancy; And our doctors maintaining custody of that biologic as we take directly from the hospital delivery room and into our laboratory.

From a clinical perspective we provide and employ the best medical team with decades of combine history in the field. With patient follows up and tracking to ensure best outcomes and, importantly, we compile and share statistically significant data to help lift the entire industry.

And we do everything following AABB guidelines, an FDA proxy, and we invite oversight by both local and international governing bodies whenever able. The day will come when the United States will consider changing the regulations on stem cell expansion. And when that opportunity arrives, Auragens has the evidence, this history, the outcomes, and the documentation of having run an FDA look-a-like program, with outstanding results.

One day we look forward to helping make this treatment available to all and in every geography; Until that day we look forward to helping you at Auragens, in the financial and culture hub of Latin America, Panama City, Panama.

🔗 Share this newsletter on social media.